About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment

by Medindia Content Team on February 20, 2006 at 11:58 AM
Font : A-A+

New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment

FAS20013, a tuberculosis drug, currently in the experimental phase has offered hope in the treatment of multiple drug resistant and latent infections as well. The mechanism of action of the new drug is different than those used for conventional treatment.

The drug targets slow growing mycobacteria involved in the disease process and induces selective killing of the same. The other drugs target a broad spectrum of non-pathogenic microorganisms that enables development of drug resistance. Nearly all isolates have been shown to be susceptible to the compound and no resistance has been observed.

Advertisement

The compound is the first ever known to combat latent infection. Following infection, some patients go into a latent phase where no symptoms are seen. Such patients are not capable of infecting others, as they do not have an active infection. However, they can develop active infection at any time. Worldwide, more than 2 billion people have this latent form of the disease.

Furthermore, the drug action is precipitated in just 4 hours while Rifampicin or Isoniazid needs 12 to 14 hours to destroy the pathogen. The pharmaceutical company FASgen, Inc., is working towards marketing the novel drug for commercial use.
Advertisement

Overcoming multiple drug resistance in tuberculosis represents a significant challenge in the successful treatment of tuberculosis. It is associated with a fatality rate ranging from 20 to 80%. The presence of an uncontrollable active infection and failure to respond to any therapy are strong indications for isolation of the patient to prevent the emergence of drug resistant strains in the population. In worst cases, it may be even required to perform surgical resection of a part of the lung. The cost associated with such a treatment can be as high as $250,000.

The drug is currently being investigated in laboratory animals to estimate the beneficial and toxic effects. An application would soon be submitted to the Food and Drug Administration (FDA) regarding proceeding with clinical trials of the investigational new drug (IND). If promising results are obtained, we could soon have an anti-tuberculous drug for treatment of MDR-TB.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Monkeypox Outbreak: What it is, How Does it Spread & the Prevention
Seasonal Allergy Medications
How to Choose the Best Eczema-Friendly Moisturizer for Children?
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Tuberculosis AIDS/HIV Clinical Trials - Different Phases of the trial Signature Drug Toxicity Silicosis Screening Tests for Tuberculosis 

Most Popular on Medindia

Drug - Food Interactions Diaphragmatic Hernia Noscaphene (Noscapine) Iron Intake Calculator Blood Donation - Recipients Drug Interaction Checker How to Reduce School Bag Weight - Simple Tips Daily Calorie Requirements Blood Pressure Calculator Sanatogen

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use